NASDAQ: DXCMDexcom Inc Stock
$72.47+1.24 (+1.74%)
Updated Jun 18, 2026
DXCM Price
$72.47
Fair Value Price
$71.46
Market Cap
$27.96B
52 Week Low
$54.11
52 Week High
$89.98
P/E
30.2x
P/B
9.46x
P/S
5.02x
PEG
1.94x
Dividend Yield
N/A
Revenue
$4.82B
Earnings
$930.40M
Gross Margin
61.5%
Operating Margin
25.36%
Profit Margin
19.3%
Debt to Equity
1.24
Operating Cash Flow
$2B
Beta
1.13
Next Earnings
Jul 29, 2026
Ex-Dividend
N/A
Next Dividend
N/A
DXCM Overview
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DXCM's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
DXCM
Ranked#9 of 93
Ranked#9 of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $38.68 | A | |
| $26.62 | A |
Be the first to know about important DXCM news, forecast changes, insider trades & much more!
DXCM News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DXCM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DXCM ($72.47) is overvalued by 1.42% relative to our estimate of its Fair Value price of $71.46 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DXCM ($72.47) is not significantly undervalued (1.42%) relative to our estimate of its Fair Value price of $71.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DXCM ($72.47) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DXCM due diligence checks available for Premium users.
Valuation
DXCM fair value
Fair Value of DXCM stock based on Discounted Cash Flow (DCF)
Price
$72.47
Fair Value
$71.46
Overvalued by
1.42%
DXCM ($72.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DXCM ($72.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DXCM ($72.47) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DXCM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
30.2x
Industry
20.08x
Market
9.47x
DXCM is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DXCM is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
DXCM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.46x
Industry
2.95x
DXCM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DXCM price to earnings growth (PEG)
For valuing profitable companies with growth potential
DXCM is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
DXCM's financial health
Profit margin
Revenue
$1.2B
Net Income
$199.5M
Profit Margin
16.7%
DXCM's Earnings (EBIT) of $1.22B... subscribe to Premium to read more.
Interest Coverage Financials
DXCM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.6B
Liabilities
$3.7B
Debt to equity
1.24
DXCM's short-term assets ($4.33B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DXCM's short-term assets ($4.33B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DXCM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DXCM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$525.6M
Investing
-$298.5M
Financing
-$25.0M
DXCM's operating cash flow ($1.78B)... subscribe to Premium to read more.
Debt Coverage Financials
DXCM vs Medical Device Stocks
Dexcom Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.